Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$99.5B	$790 Million 0.14% of portfolio	1,773,625	Q2 2025 Added 2.8%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$378 Million 0.07% of portfolio	720,273	Q2 2025 Added 1.4%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$186 Million 0.03% of portfolio	571,747	Q2 2025 Added 3.09%
EXEL Exelixis, Inc.	$12.1B	$143 Million 0.03% of portfolio	3,236,075	Q2 2025 Reduced 2.57%
INSM Insmed Inc	$16.5B	$131 Million 0.02% of portfolio	1,299,568	Q2 2025 Reduced 18.91%
INCY Incyte Corp	$18.2B	$114 Million 0.02% of portfolio	1,671,138	Q2 2025 Reduced 0.65%
RPRX Royalty Pharma PLC	$15.7B	$108 Million 0.02% of portfolio	3,008,837	Q2 2025 Reduced 3.64%
UTHR United Therapeutics Corp	$13.7B	$96.5 Million 0.02% of portfolio	335,885	Q2 2025 Reduced 4.27%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$85.5 Million 0.02% of portfolio	1,556,117	Q2 2025 Added 1.55%
MRNA Moderna, Inc.	$10B	$83.9 Million 0.02% of portfolio	3,040,117	Q2 2025 Added 15.6%
TECH Bio Techne Corp	$2.07B	$79.9 Million 0.01% of portfolio	1,552,440	Q2 2025 Added 2.72%
BPMC Blueprint Medicines Corp	$7.73B	$71.9 Million 0.01% of portfolio	561,159	Q2 2025 Reduced 6.43%
HALO Halozyme Therapeutics, Inc.	$8.95B	$69.9 Million 0.01% of portfolio	1,342,831	Q2 2025 Reduced 23.22%
CORT Corcept Therapeutics Inc	$7.88B	$59.8 Million 0.01% of portfolio	814,455	Q2 2025 Reduced 21.06%
RVMD Revolution Medicines, Inc.	$3.09B	$58.9 Million 0.01% of portfolio	1,600,693	Q2 2025 Reduced 17.08%
IONS Ionis Pharmaceuticals Inc	$5.85B	$58.8 Million 0.01% of portfolio	1,487,818	Q2 2025 Added 3.06%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$57.5 Million 0.01% of portfolio	1,331,473	Q2 2025 Added 3.84%
JAZZ Jazz Pharmaceuticals PLC	$7.1B	$54.7 Million 0.01% of portfolio	515,075	Q2 2025 Reduced 16.35%
TGTX Tg Therapeutics, Inc.	$3.94B	$47.4 Million 0.01% of portfolio	1,316,496	Q2 2025 Added 4.24%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$46.3 Million 0.01% of portfolio	153,085	Q2 2025 Added 1.21%
PCVX Vaxcyte, Inc.	$1.78B	$46.1 Million 0.01% of portfolio	1,417,711	Q2 2025 Added 6.32%
ADMA Adma Biologics, Inc.	$3.29B	$45.6 Million 0.01% of portfolio	2,502,026	Q2 2025 Added 1.63%
CRSP Crispr Therapeutics Ag	$4.42B	$45.4 Million 0.01% of portfolio	933,204	Q2 2025 Added 30.79%
CYTK Cytokinetics Inc	$3.23B	$44.8 Million 0.01% of portfolio	1,357,117	Q2 2025 Added 3.37%
AXSM Axsome Therapeutics, Inc.	$4.51B	$37.2 Million 0.01% of portfolio	356,651	Q2 2025 Added 5.75%
PTCT Ptc Therapeutics, Inc.	$3.24B	$34.6 Million 0.01% of portfolio	707,704	Q2 2025 Added 6.89%
KRYS Krystal Biotech, Inc.	$3.69B	$33.8 Million 0.01% of portfolio	246,180	Q2 2025 Reduced 1.73%
AKRO Akero Therapeutics, Inc.	$2.23B	$32.8 Million 0.01% of portfolio	614,266	Q2 2025 Added 5.5%
ROIV Roivant Sciences Ltd.	$8.15B	$32.6 Million 0.01% of portfolio	2,889,082	Q2 2025 Added 1.46%
PTGX Protagonist Therapeutics, Inc	$2.68B	$31.8 Million 0.01% of portfolio	575,364	Q2 2025 Added 3.16%
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$31.2 Million 0.01% of portfolio	1,436,112	Q2 2025 Added 8.24%
RNA Avidity Biosciences, Inc.	$2.41B	$29.8 Million 0.01% of portfolio	1,048,219	Q2 2025 Added 2.41%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$29.2 Million 0.01% of portfolio	461,438	Q2 2025 Added 3.59%
BNTX Bio N Tech Se	$26.9B	$28 Million 0.01% of portfolio	262,993	Q2 2025 Added 8.02%
SMMT Summit Therapeutics Inc.	$5.17B	$27.5 Million 0.0% of portfolio	1,291,671	Q2 2025 Reduced 11.57%
NUVL Nuvalent, Inc.	$3.29B	$26.4 Million 0.0% of portfolio	346,506	Q2 2025 Added 9.05%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$25.7 Million 0.0% of portfolio	1,189,861	Q2 2025 Reduced 0.91%
SRRK Scholar Rock Holding Corp	$1.66B	$22.5 Million 0.0% of portfolio	635,891	Q2 2025 Added 3.04%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$22.4 Million 0.0% of portfolio	615,969	Q2 2025 Added 3.85%
CRNX Crinetics Pharmaceuticals, Inc.	$1.53B	$22 Million 0.0% of portfolio	766,228	Q2 2025 Added 1.69%
NVO Novo Nordisk A S	$112B	$21.7 Million 0.0% of portfolio	314,627	Q2 2025 Added 20.43%
VCYT Veracyte, Inc.	$2.06B	$21.1 Million 0.0% of portfolio	780,940	Q2 2025 Added 5.44%
ACLX Arcellx, Inc.	$3.19B	$21 Million 0.0% of portfolio	319,272	Q2 2025 Reduced 5.25%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$20.3 Million 0.0% of portfolio	432,624	Q2 2025 Reduced 29.64%
LGND Ligand Pharmaceuticals Inc	$2.58B	$20 Million 0.0% of portfolio	176,064	Q2 2025 Added 4.26%
VCEL Vericel Corp	$1.72B	$19.9 Million 0.0% of portfolio	467,424	Q2 2025 Added 3.96%
MIRM Mirum Pharmaceuticals, Inc.	$2.38B	$19.5 Million 0.0% of portfolio	383,160	Q2 2025 Added 16.86%
VKTX Viking Therapeutics, Inc.	$3.06B	$19.3 Million 0.0% of portfolio	727,420	Q2 2025 Added 2.18%
KYMR Kymera Therapeutics, Inc.	$2.18B	$18.7 Million 0.0% of portfolio	429,304	Q2 2025 Added 12.47%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$18.5 Million 0.0% of portfolio	1,170,745	Q2 2025 Added 13.08%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.